Press Release: Tuesday 25 August 2026
Statement from the Minister for Health on HSE approval of reimbursement of Skyclarys for patients with Friedreich’s Ataxia
Today is an important day for those with Friedreich’s Ataxia and their families, some of whom I have met. It is an important day in a world where their disease brings far too much uncertainty.
Though I know the statutory process through which these decisions are made is complex, it is important that politics and politicians allow the space for science to be the decision maker.
At a time when there is too much uncertainty in the world, Ireland will continue to stick to science and to the rule of law. Simply put, these processes must be independent and led by experts.
I am grateful to our Health Service Executive (HSE) scientists and to our commercial team involved in the negotiations for their continued and active engagement to reach today’s decision and I thank the manufacturer for their intensive engagement, especially in recent days.
I am grateful to the patients who have so carefully articulated their lived experiences. I am also grateful to the many clinicians who provided the HSE’s Senior Management Team with their expertise and advice to make their decision today.
The HSE will now engage with the company to put in place the process by which patients can gain access to the drug. I have asked that this work commence immediately.